The Uromigos
Advertisement
Recent data that showed higher OS after exercise in patients with colorectal cancer are reviewed in the context of GU cancer.
Dr. Silke Gillessen joins the show to discuss highlights from the ASCO 2025 Annual Meeting with Brian and Tom.
Dr. Joshua Meeks joins the podcast to give a stellar overview of emerging data in the NMIBC space.
Dr. Gerhardt Attard discusses practice-changing data from AMPLITUDE, and the history of PARP inhibitor use.
Dr. Nick James discusses data from STAMPEDE on the use of AI to predict benefit from ADT + abiraterone.
Dr. Jorge Garcia discusses the process of selecting abstracts for oral presentation.
Dr. Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Dr. Matt Galsky discusses the 2025 ASCO Annual Meeting data regarding ctDNA from the NIAGARA study.
Dr. Jeannie Hoffman-Censits discusses her randomized phase 2 trial on adding sacituzumab govitecan to maintenance avelumab.
Dr. Michiel Van Der Heijden joins the podcast to discuss his trial on ipilimumab + nivolumab vs chemotherapy randomization.
Dr. Monty Pal discusses more correlative data from the IMmotion010 trial, including matched baseline samples.
Dr. McDermott recaps his discussion on biomarkers in kidney cancer from the 2025 ASCO Annual Meeting.
Returning guest Silke Gillessen joins the show to chat with Tom and Brian on what they are looking forward to at ASCO 2025.
Returning guests Drs. Gillessen and Sweeney discuss the value of treatments for advanced prostate cancer.
Dr. Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1.
Dr. Viktor Grünwald joins the show to discuss the new data session from the European International Kidney Cancer Symposium.
Dr. Mark Tyson from Mayo Clinic joins the podcast to discuss the high CR rate seen in cohort C of the BOND-003 trial.
Dr. Neal Shore joins the show to discuss exciting data from the CREST trial.
Part 2 dives deeper into the explosion of ADC clinical drug development in China.
Drs. Dingwei Ye and Yao Zhu join the show to discuss drug development in China amid the recent surge of GU clinical trials.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.